Year of publication: 2024

SIRS 2024

Long-Term Metabolic Outcomes Associated With KarXT (Xanomeline and Trospium): Interim Results From Pooled, Long-Term Safety Studies EMERGENT-4 and EMERGENT-5

SIRS 2024

The Impact of KarXT on Cognitive Impairment in Acute Schizophrenia: Replication in Pooled Data From Phase 3 Trials

SIRS 2024

Maintenance of Efficacy of KarXT (Xanomeline and Trospium) in Schizophrenia

SIRS 2024

Long-Term Safety of KarXT (Xanomeline and Trospium) in Schizophrenia

SIRS 2024

Blinded Remote Ratings of Site-Based PANSS Interviews Address Functional Unblinding in a Study of Acute Exacerbation of Psychosis in Schizophrenia

ISCTM 2024

Further Evaluation of the Procognitive Effect of KarXT in Acutely Symptomatic Schizophrenia: Consideration of Cognitive Subdomains and Methodological Factors